CAJ | 학술논문

目的：分析非小细胞肺癌( NSCLC)患者外周血T细胞亚群、NK细胞的表达,及其与临床分期及预后的相关性。方法采用流式细胞术检测96例NSCLC患者、30例肺部良性疾病及健康体检者外周血T细胞亚群、NK细胞的表达,分析其与肺癌临床分期的关系,对患者随访2年,比较化疗后不同表达水平之间的生存率。结果 NSCLC组患者CD3+、CD4+/CD8+及NK细胞比例较对照组和肺良性疾病组明显降低,而CD8+细胞比例则明显升高( P<0．05)；Ⅲ-Ⅳ期NSCLC患者CD3+及NK细胞比例较Ⅰ-Ⅱ期患者明显降低,而CD8+细胞比例则明显升高(P<0．05)；CD3+、CD4+/CD8+及NK细胞与临床分期呈负相关(r=-0．715、-0．673、-0．593,P<0．05),CD8+与临床分期呈正相关(r=0．672,P<0．05)；CD4+/CD8+上升组化疗后2年生存率为82．0%,明显高于未上升组57．6%,差异均有统计学意义( P<0．05)。结论 NSCLC患者外周血T细胞亚群、NK细胞分布异常,且与临床分期密切相关,联合检测可客观反映免疫功能状态及病情程度,对NSCLC的治疗及预后具有一定的指导作用。
목적：분석비소세포폐암( NSCLC)환자외주혈T세포아군、NK세포적표체,급기여림상분기급예후적상관성。방법채용류식세포술검측96례NSCLC환자、30례폐부량성질병급건강체검자외주혈T세포아군、NK세포적표체,분석기여폐암림상분기적관계,대환자수방2년,비교화료후불동표체수평지간적생존솔。결과 NSCLC조환자CD3+、CD4+/CD8+급NK세포비례교대조조화폐량성질병조명현강저,이CD8+세포비례칙명현승고( P<0．05)；Ⅲ-Ⅳ기NSCLC환자CD3+급NK세포비례교Ⅰ-Ⅱ기환자명현강저,이CD8+세포비례칙명현승고(P<0．05)；CD3+、CD4+/CD8+급NK세포여림상분기정부상관(r=-0．715、-0．673、-0．593,P<0．05),CD8+여림상분기정정상관(r=0．672,P<0．05)；CD4+/CD8+상승조화료후2년생존솔위82．0%,명현고우미상승조57．6%,차이균유통계학의의( P<0．05)。결론 NSCLC환자외주혈T세포아군、NK세포분포이상,차여림상분기밀절상관,연합검측가객관반영면역공능상태급병정정도,대NSCLC적치료급예후구유일정적지도작용。
Objective To investigate the expression of T lymphocyte subsets and NK cells in patients with non-small cell lung cancer ( NSCLC) , and to analyze their relationship with clinical stage and prognosis. Methods The expression of T lymphocyte subsets and NK cells was detected in 96 patients with NSCLC, 30 patients with be-nign pulmonary disease and 30 healthy controls by flow cytometry. Their relationship with clinical stage was analyzed. All the patients were followed up for 2 years, and the survival rates after chemotherapy between different expression of T lymphocyte subsets and NK cells were compared. Results The proportions of CD3+, CD4+ /CD8+ and NK cells in NSCLC patients were significantly lower than those in the control group and patients with benign pulmonary disease, and the proportion of CD8+ increased remarkably ( P<0. 05 ) . The proportions of CD3+ and NK cells at the clinical stage of Ⅲ-Ⅳ were lower, and CD8+ was higher than those at the clinical stage of Ⅰ-Ⅱ (P<0. 05). The level of CD3+, CD4+ /CD8+ and NK cells was negatively correlated with clinical stage (r= -0. 715, -0. 673, -0. 5931, P<0. 05), but the level of CD8+ was positively correlated with clinical stage in NSCLC patients (r =0. 672, P <0. 05). The two-year survival rate after chemotherapy in patients with CD4+ /CD8+ increase was 82. 0%, which was significantly higher than 57. 6% in patients with no increase of CD4+ /CD8+(P<0. 05). Conclusion Abnormal dis-tribution of T lymphocyte subsets and NK cells occurs in NSCLC patients, and it is closely related with clinical sta-ges. The combined detection can objectively reflect the state of immune function and degree of condition, which shows some meaningful effect to the comprehensive treatment and prognosis.